683 Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

683 Capital Management’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,488	Closed	-$2.73M	–	410
2021 Q4	$2.73M	Sell	4,488 -2,429	-35%	-$2.28M	0.1%	117
2021 Q3	$6.79M	Buy	6,917 +2,048	+42%	+$2.56M	0.26%	75
2021 Q2	$7.27M	Buy	4,869 +3,534	+265%	+$7.7M	0.25%	75
2021 Q1	$3.59M	Sell	1,335 -1,258	-49%	-$2.49M	0.19%	82
2020 Q4	$5.11M	Hold	2,593	–	–	0.24%	67
2020 Q3	$7M	Buy	2,593 +1,889	+268%	+$4.71M	0.51%	45
2020 Q2	$2M	Hold	704	–	–	0.16%	79
2020 Q1	$1.88M	Buy	704 +482	+217%	+$1.44M	0.22%	71
2019 Q4	$567K	Buy	+222	New	+$289K	0.06%	79

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

683 Capital Management's APTO Position: Q1 2022 in Review

683 Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q1 2022, closing a stake of 4,488 shares — an estimated $2.73M sold.

683 Capital Management first reported a position in APTO in Q4 2019 and held it in 9 quarters. The position peaked at $7.27M in Q2 2021. 52 funds tracked by Wall St. Rank hold APTO as of Q1 2022.

683 Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
683 Capital Management sold 4,488 Aptose Biosciences, Inc. shares in Q1 2022, an estimated $2.73M.
683 Capital Management first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 9 quarters.
683 Capital Management's Aptose Biosciences, Inc. position peaked at $7.27M in Q2 2021.
52 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2022.

Based on 683 Capital Management's 13F filing for Q1 2022, filed 16 May 2022.